639 filings
PRE 14A
VXRT
Vaxart Inc
Preliminary proxy
18 Apr 24
4:10pm
S-8
VXRT
Vaxart Inc
14 Mar 24
Registration of securities for employees
4:56pm
10-K
2023 FY
VXRT
Vaxart Inc
Annual report
14 Mar 24
4:46pm
8-K
VXRT
Vaxart Inc
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
VXRT
Vaxart Inc
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
4gy20ar lb8v
29 Feb 24
Departure of Directors or Certain Officers
4:30pm
8-K
zmka sm4x
15 Feb 24
Other Events
4:10pm
8-K/A
awdgp 44p
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K
sauk5182zt32sh2rorxy
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
ce3nqneb3f2 7fid6
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
51tqyc2m sr
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
l5vw1urg8l
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
enel ukrvde3
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K/A
6ekmu4 ki
23 Oct 23
Submission of Matters to a Vote of Security Holders
5:09pm
8-K
0e5hx3j56 w69dl8a
23 Oct 23
Amendments to Articles of Incorporation or Bylaws
5:01pm
8-K
j6zgbm4uzd9vib cc
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
lpsd8sbzfizt3m2nj1
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
wxmqzs
26 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm